Craig-Hallum lowered the firm’s price target on Simulations Plus (SLP) to $31 from $36 and keeps a Buy rating on the shares. The firm notes the company reported final Q3 results with revenues slightly ahead of the pre-release range and revenue guidance for FY25 reaffirmed. Craig-Hallum believes that the headwinds the company is facing will be relatively short-term in nature and given the recent regulatory guidance which calls for more use of AI/simulation in the discovery and development of pharmaceuticals, the firm thinks Simulations Plus will return to double-digit revenue growth and adjusted EBITDA margins of 30%-plus.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLP:
- Simulations Plus price target lowered to $20 from $28 at Stephens
- Simulations Plus: Strong Financial Performance and Growth Potential Justify Buy Rating
- Simulations Plus: Strong Q3 Performance and Strategic Positioning Justify Buy Rating Despite Challenges
- Simulations Plus downgraded to Sector Weight from Overweight at KeyBanc
- Simulations Plus Reports Q3 2025 Financial Results